Profile data is unavailable for this security.
About the company
Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Company’s main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimer’s disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.
- Revenue in HKD (TTM)6.95bn
- Net income in HKD847.89m
- Incorporated2003
- Employees5.27k
- LocationLuye Pharma Group LtdNo.15 Chuangye Road, High-Tech ZoneYANTAI 264003ChinaCHN
- Phone+86 5 356717618
- Fax+86 5 356717718
- Websitehttps://www.luye.cn/lvye/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tong Ren Tang Technologies Co Ltd | 7.57bn | 716.19m | 6.19bn | 4.01k | 8.64 | 0.7922 | 4.32 | 0.8174 | 0.5592 | 0.5592 | 5.91 | 6.10 | 0.5026 | 0.9881 | 5.22 | 1,845,461.00 | 7.42 | 7.68 | 11.69 | 12.32 | 40.97 | 43.50 | 14.76 | 16.11 | 2.30 | -- | 0.1968 | 39.94 | 13.04 | 6.01 | 1.25 | -2.73 | -22.26 | -0.0089 |
| Beijing Tong Ren Tang Chinese Medicine | 1.38bn | 494.14m | 6.29bn | 779.00 | 12.74 | 1.65 | 10.18 | 4.57 | 0.5903 | 0.5903 | 1.64 | 4.55 | 0.3284 | 0.3554 | 3.62 | 1,725,133.00 | 12.72 | 16.71 | 14.09 | 18.75 | 72.06 | 69.88 | 38.72 | 40.72 | 9.55 | -- | 0.0327 | 68.87 | -11.91 | 0.1459 | -16.33 | -1.43 | -16.30 | 7.49 |
| China Shineway Pharmaceutical Group Ltd | 4.63bn | 1.22bn | 6.50bn | 3.44k | 4.88 | 0.8051 | 4.67 | 1.40 | 1.61 | 1.61 | 6.13 | 9.76 | 0.4476 | 1.28 | 5.26 | 1,346,646.00 | 11.76 | 8.03 | 15.47 | 9.77 | 75.21 | 74.55 | 26.27 | 17.87 | 3.14 | -- | 0.0457 | 36.29 | 14.32 | 11.94 | 34.14 | 13.89 | 0.6396 | 12.88 |
| Yichang Hec Changjiang Pharmactcl Co Ltd | 6.10bn | 1.81bn | 7.21bn | 4.89k | 3.97 | 0.7558 | 3.42 | 1.18 | 2.06 | 2.06 | 6.93 | 10.84 | 0.4272 | 2.50 | 3.57 | 1,320,291.00 | 11.69 | 8.03 | 17.27 | 11.81 | 78.90 | 79.97 | 27.37 | 20.80 | 1.93 | 25.51 | 0.2126 | 15.81 | 68.08 | 20.18 | 2,501.24 | 16.15 | -11.50 | -- |
| Everest Medicines Ltd | 460.62m | -1.16bn | 7.45bn | 520.00 | -- | 1.51 | -- | 16.17 | -3.60 | -3.60 | 1.43 | 15.13 | 0.0756 | 5.23 | 3.22 | 1,066,239.00 | -19.03 | -30.52 | -20.21 | -33.14 | 75.74 | -- | -251.64 | -5,745.25 | 4.62 | -- | 0.1119 | -- | 884.46 | -- | -241.50 | -- | 4.65 | -- |
| Cansino Biologics Inc | 670.77m | -953.77m | 7.84bn | 1.49k | -- | 0.8896 | -- | 11.69 | -3.86 | -3.86 | 2.72 | 22.54 | 0.0676 | 1.28 | 0.8385 | 448,974.00 | -10.15 | -4.27 | -13.73 | -5.60 | 14.38 | -- | -150.19 | -27.72 | 2.19 | -- | 0.3028 | -- | -66.52 | 213.94 | -63.04 | -- | 30.60 | -- |
| Luye Pharma Group Ltd | 6.95bn | 847.89m | 11.36bn | 5.27k | 13.40 | 0.7929 | 6.66 | 1.64 | 0.2254 | 0.2254 | 1.85 | 3.81 | 0.236 | 2.44 | 2.84 | 1,318,408.00 | 3.11 | 2.80 | 5.47 | 4.45 | 68.73 | 70.53 | 13.18 | 10.39 | 1.20 | 2.96 | 0.4016 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| SSY Group Ltd | 6.47bn | 1.37bn | 11.39bn | 5.80k | 8.36 | 1.57 | 6.23 | 1.76 | 0.4593 | 0.4593 | 2.18 | 2.44 | 0.5418 | 2.75 | 3.07 | 1,155,141.00 | 11.54 | 10.51 | 14.88 | 14.03 | 54.39 | 58.72 | 21.30 | 18.62 | 2.06 | 28.65 | 0.323 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
| Shanghai Henlius Biotech Inc | 6.21bn | 761.91m | 12.58bn | 3.55k | 16.55 | 4.43 | 10.77 | 2.03 | 1.40 | 1.40 | 11.37 | 5.22 | 0.5764 | 1.90 | 6.82 | 1,706,729.00 | 7.07 | -8.59 | 14.25 | -14.14 | 73.23 | 71.77 | 12.27 | -27.37 | 0.329 | 6.86 | 0.6113 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| 3SBio Inc | 9.27bn | 1.83bn | 13.49bn | 5.61k | 7.51 | 0.8452 | 5.96 | 1.46 | 0.7493 | 0.7493 | 3.80 | 6.66 | 0.3575 | 1.52 | 6.73 | 1,712,778.00 | 7.25 | 7.44 | 10.26 | 9.29 | 85.94 | 82.91 | 20.27 | 21.50 | 1.57 | 23.87 | 0.1998 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| Grand Pharmaceutical Group Ltd | 10.59bn | 2.41bn | 15.05bn | 10.78k | 6.16 | 0.9575 | 5.23 | 1.42 | 0.6885 | 0.6885 | 3.03 | 4.43 | 0.4472 | 3.62 | 3.21 | 1,005,064.00 | 10.25 | 10.09 | 14.21 | 14.01 | 59.00 | 61.97 | 22.92 | 22.35 | 1.09 | -- | 0.2232 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
| The United Laboratories Intl. Hldgs Ltd. | 15.42bn | 3.20bn | 15.24bn | 15.00k | 4.76 | 1.02 | 3.99 | 0.9888 | 1.76 | 1.76 | 8.48 | 8.19 | 0.6578 | 3.30 | 3.54 | 1,027,797.00 | 13.65 | 7.89 | 20.72 | 12.64 | 46.15 | 44.17 | 20.75 | 12.73 | 1.72 | -- | 0.1532 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 46.04 |
| Simcere Pharmaceutical Group Ltd | 6.98bn | -1.21bn | 15.69bn | 7.03k | -- | 2.14 | -- | 2.25 | -0.4638 | -0.4638 | 2.71 | 2.91 | 0.5198 | 2.19 | 2.64 | 993,214.30 | -9.04 | 10.17 | -11.71 | 15.60 | 77.02 | 78.82 | -17.40 | 17.50 | 1.88 | 0.4709 | 0.1461 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| Zai Lab Ltd | 2.51bn | -2.32bn | 16.28bn | 2.18k | -- | 2.92 | -- | 6.47 | -2.39 | -2.39 | 2.59 | 5.59 | 0.3083 | 3.04 | 5.52 | -- | -28.50 | -37.72 | -34.92 | -42.72 | 63.17 | 64.75 | -92.44 | -282.44 | 3.29 | -- | 0.0908 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
Data as of Sep 20 2024. Currency figures normalised to Luye Pharma Group Ltd's reporting currency: Hong Kong Dollar HKD
23.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Zhong Geng Fund Management Co. , Ltd.as of 31 Dec 2023 | 288.78m | 7.68% |
| E Fund Management Co., Ltd.as of 10 Aug 2023 | 184.79m | 4.91% |
| UBS Asset Management Switzerland AGas of 02 Sep 2024 | 158.03m | 4.20% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 70.82m | 1.88% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 50.65m | 1.35% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 43.01m | 1.14% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 42.23m | 1.12% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 23.89m | 0.64% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 11.96m | 0.32% |
| American Century Investment Management, Inc.as of 05 Sep 2024 | 6.66m | 0.18% |
More ▼
Data from 31 Dec 2023 - 12 Sep 2024Source: FactSet Research Systems Inc.
